Non-Hodgkin lymphoma (NHL) is the major subtype of lymphoma with an estimated 544,352 new cases globally in 2020 [ 1 ], and an increasing trend in incidence has been observed in Japan due to aging demographic trends [ 2 , 3 ].
← all excerpts
Cost-effectiveness analysis 3L of axicabtagene ciloleucel vs tisagenlecleucel and lisocabtagene maraleucel in Japan.
1
—
—